Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

S063 - Pearls from the Masters of Dermatological Surgery

Monday, February 19; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Demonstrate new concepts in dermatologic oncology and cosmetic dermatology.
  • Determine the subtleties of toxins, fillers and devices.
  • Describe new surgical repairs for dermatologic problems in clinical practice.


This fast-moving session is highly popular with the attendees and the speakers. Each speaker has been selected for their experience and teaching reputation in dermatologic oncology/laser surgery or cosmetic dermatology. Each speaker will present 1-3 pearls in rapid fire fashion. The pearls are all designed to be immediately relevant to clinical practice. Please join us for this highly practical and interactive session.


  • Aasi, Sumaira Zareen, MD: no financial relationships exist with commercial interests.
  • Arron, Sarah T., MD, PhD: Amyris, Inc. – C(Fees); DUSA Pharmaceuticals – I(S); Eli Lilly and Company – I(S); Genentech, Inc. – E(S), I(S); Kiniksa Pharmaceuticals, Ltd. – I(S); LEO Pharma, US – I(S); Menlo Therapeutics – I(S); Pfizer Inc. – I(S); Sun Pharmaceutical Industries Ltd. – I(S); Zebra Medical Technologies – C(Fees);
  • Butterwick, Kimberly J., MD: Allergan, Inc – I(Grants/Research Funding); Allergan, Inc. – A(H); Colorescience – A(H); Galderma Laboratories, L.P. – A(H); Merz Pharmaceuticals, LLC – A(H); Revance Therapeutics, Inc. – A(H); ThermiAesthetics – C(H); Valeant Pharmaceuticals International – C(H);
  • Eisen, Daniel Brian, MD: no financial relationships exist with commercial interests.
  • Greenway, Hubert T., Jr., MD: Consortium for Global Education – A(NC), SP(NC); Superfoods RX – F(ST); UCSD, Anat/Surg CME Course – F(H), SP(NC);
  • Gross, Kenneth G., MD: no financial relationships exist with commercial interests.
  • Hanke, C. William, MD: Allergan, Inc. – I(Grants/Research Funding); Dermavance – I(Grants/Research Funding); Educational Testing and Assessment Systems, Inc. (ETAS) – O(H); Elsevier Inc. – O(IP); Genentech, Inc. – A(NC), I(Grants/Research Funding), SP(H); Informa HealthCare – O(IP); Kythera – I(Grants/Research Funding); LEO Pharma, US – A(H), C(H), I(Grants/Research Funding); Orlando Dermatology Aesthetic & Clinical (ODAC) – C(H); Sanova Works – O(H); Springer Science & Business Media – O(IP);
  • Kaufman, Andrew J., MD: no financial relationships exist with commercial interests.
  • Kilmer, Suzanne L., MD: Allergan, Inc – I(Grants/Research Funding); Cutera, Inc. – I(Grants/Research Funding); Cynosure, Inc. – I(Grants/Research Funding); Cytrellis Biosystems, Inc – A(Grants/Research Funding); Galderma USA – A(H); Lumenis – I(Grants/Research Funding); Lutronics, Inc. – I(Grants/Research Funding); Merz Aesthetics – I(Grants/Research Funding); Miramar Labs – A(H); R2 Dermatology, Inc. – I(Grants/Research Funding); Sebacia, Inc. – I(Grants/Research Funding); Sienna Labs, Inc. – A(H); Solta Medical – I(Grants/Research Funding); Syneron Candela – A(Grants/Research Funding); Zarin Medical – A(H); Zeltiq Aesthetics – A(H); Zift Medical – A(H);
  • Moy, Ronald L., MD: DNA EGF Renewal – F(NC);
  • Omlin, Kenny J., MD: no financial relationships exist with commercial interests.
  • Palm, Melanie, MD: Allergan, Inc – A(H); AmperSand Biopharmaceutical, LLC – I(Fees); BTL Industries – Speaker/Faculty Education(H); Galderma Laboratories, L.P. – C(H); Kythera – Speaker/Faculty Education(H); Lumenis – SP(H); Lutronics, Inc. – C(OB); Merz Aesthetics – Speaker/Faculty Education(H); Valeant Pharmaceuticals International – C(H);
  • Ross, E. Victor, Jr., MD: Candela Corporation – A(Grants/Research Funding), I(H); Cutera, Inc. – I(EQ), I(Grants/Research Funding); Lumenis – I(EQ), I(H); Sebcaia, Inc – A(H); Syneron, Inc. – I(Grants/Research Funding);
  • Rotunda, Adam M., MD: Kythera – A(ST);
  • Schlesinger, Todd, MD: Abbott Laboratories – I(Grants/Research Funding); Allergan, Inc – C(H), I(Grants/Research Funding); Amgen – I(Grants/Research Funding); Astellas Pharma US, Inc – I(Grants/Research Funding); Bayer – SP(H); Centocor Ortho Biotech Inc. – I(Grants/Research Funding); Coherus Biosciences – I(Grants/Research Funding); Corrona, Inc. – I(Grants/Research Funding); Genentech, Inc. – I(Grants/Research Funding); Innocutis – C(S); Janssen Pharmaceuticals, Inc – I(Grants/Research Funding); Regeneron – I(Grants/Research Funding); Sebacia, Inc. – I(Grants/Research Funding); Sienna Biopharmaceuticals – I(Grants/Research Funding); Suneva Medical, Inc. – A(H), Speaker/Faculty Education(H); Valeant Pharmaceuticals North America LLC – I(Grants/Research Funding);
  • Shumaker, Peter Randall, MD: no financial relationships exist with commercial interests.
Monday, February 19
1:00 PM
Dr. Hanke / Introduction
1:05 PM
Dr. Eisen / Eisen Pearls
1:15 PM
Dr. Kilmer / Kilmer Pearls
1:25 PM
Dr. Arron / Arron Pearls
1:35 PM
Dr. Kaufman / Kaufman Pearls
1:45 PM
Dr. Rotunda / Rotunda Pearls
1:55 PM
Dr. Aasi / Aasi Pearls
2:05 PM
Dr. Gross / Gross Pearls
2:15 PM
Dr. Omlin / Omlin Pearls
2:25 PM
Dr. Moy / Moy Pearls
2:35 PM
Dr. Ross / Ross Pearls
2:45 PM
Dr. Shumaker / Shumaker Pearls
2:55 PM
Dr. Palm / Palm Pearls
3:05 PM
Dr. Greenway / Greenway Pearls
3:15 PM
Dr. Schlesinger / Schlesinger Pearls
3:25 PM
Dr. Butterwick / Butterwick Pearls
3:35 PM
Dr. Hanke / Hanke Pearls
Event Details
  • Date
    Monday, February 19
  • Time
    1:00 PM - 4:00 PM
  • Location
    Room 30E
  • CME Credits
  • Type
  • C. William Hanke, MD, FAAD
  • Adam M. Rotunda, MD, FAAD
  • Andrew J. Kaufman, MD, FAAD
  • Daniel Brian Eisen, MD, FAAD
  • E. Victor Ross, Jr., MD, FAAD
  • Hubert T. Greenway, Jr., MD, FAAD
  • Kenneth G. Gross, MD, FAAD
  • Kenny J. Omlin, MD, FAAD
  • Kimberly J. Butterwick, MD, FAAD
  • Melanie Palm, MD, FAAD
  • Peter Randall Shumaker, MD, FAAD
  • Ronald L. Moy, MD, FAAD
  • Sarah T. Arron, MD, PhD, FAAD
  • Sumaira Zareen Aasi, MD, FAAD
  • Suzanne L. Kilmer, MD, FAAD
  • Todd Schlesinger, MD, FAAD